LB Pharmaceuticals Inc (LBRX)

Currency in USD
38.85
-1.19(-2.97%)
Closed·
38.07-0.78(-2.01%)
·
LBRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
38.5740.67
52 wk Range
15.5550.16
Key Statistics
Prev. Close
38.85
Open
39.53
Day's Range
38.57-40.67
52 wk Range
15.55-50.16
Volume
303.06K
Average Volume (3m)
370.5K
1-Year Change
153.4247%
Book Value / Share
12.95
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LBRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
58.00
Upside
+49.29%
Members' Sentiments
Bearish
Bullish
ProTips
8 analysts have revised their earnings downwards for the upcoming period

LB Pharmaceuticals Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

10 Buy
1 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 58.00
(+49.29% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Stifel
Buy53.00+36.42%-Maintain21/10/2026
H.C. Wainwright
Buy60.00+54.44%-Maintain12/10/2026
Guggenheim
Buy80.00+105.92%-Maintain12/10/2026
Canaccord
Buy65.00+67.31%-New Coverage09/10/2026
Guggenheim
Buy80.00+105.92%-New Coverage05/10/2026

Earnings

Latest Release
05/11/2026
EPS / Forecast
-1.79 / -0.99
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

LBRX Income Statement

Compare LBRX to Peers and Sector

Metrics to compare
LBRX
Peers
Sector
Relationship
P/E Ratio
−8.9x−2.9x−0.2x
PEG Ratio
−0.16−0.150.00
Price/Book
3.0x0.1x2.6x
Price / LTM Sales
-3.3x2.6x
Upside (Analyst Target)
49.3%123.6%76.9%
Fair Value Upside
Unlock14.8%14.9%Unlock

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
7.62M23.57%305.35M
Other Institutional Investors
36.20M76.43%1.45B
Public Companies & Retail Investors
0.000.00%0.00
Total
43.83M100.00%1.76B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Deep Track Capital, LP10.36%3,352,804134,313
BlackRock, Inc.8.45%2,734,305109,536

People Also Watch

12.85
NRIX
-5.51%
39.91
EWTX
-3.08%
97.17
KOD
-0.75%
54.430
LQDA
-3.88%
9.190
CLYM
-0.97%

FAQ

What Is the LB Pharmaceuticals (LBRX) Stock Price Today?

The LB Pharmaceuticals stock price today is 38.85 USD.

What Stock Exchange Does LB Pharmaceuticals Trade On?

LB Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for LB Pharmaceuticals?

The stock symbol for LB Pharmaceuticals is "LBRX."

What Is the LB Pharmaceuticals Market Cap?

As of today, LB Pharmaceuticals market cap is 1.30B USD.

What Is LB Pharmaceuticals's Earnings Per Share (TTM)?

The LB Pharmaceuticals EPS (TTM) is -4.82.

From a Technical Analysis Perspective, Is LBRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has LB Pharmaceuticals Stock Split?

LB Pharmaceuticals has split 0 times.

How Many Employees Does LB Pharmaceuticals Have?

LB Pharmaceuticals has 62 employees.

What is the current trading status of LB Pharmaceuticals (LBRX)?

As of 21/11/2026, LB Pharmaceuticals (LBRX) is trading at a price of 38.85 USD, with a previous close of 38.85 USD. The stock has fluctuated within a day range of 38.57 USD to 40.67 USD, while its 52-week range spans from 15.55 USD to 50.16 USD.

What Is LB Pharmaceuticals (LBRX) Price Target According to Analysts?

The average 12-month price target for LB Pharmaceuticals is 58.00 USD, with a high estimate of 80 USD and a low estimate of 35 USD. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +49.29% Upside potential.

What Is the LBRX After Hours Price?

LBRX's last after hours stock price is 38.07 USD, the stock has decreased by -0.78, or -2.01%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.